Publications by authors named "G Pohlmeyer-Esch"

Digitalization of pathology workflows has undergone a rapid evolution and has been widely established in the diagnostic field but remains a challenge in the nonclinical safety context due to lack of regulatory guidance and validation experience for good laboratory practice (GLP) use. One means to demonstrate that digital slides are fit for purpose, that is, provide sufficient quality for pathologists to reach a diagnosis, is conduction of comparison studies, which have been published both, for veterinary and human diagnostic pathology, but not for toxicologic pathology. Here, we present an approach that uses study material from nonclinical safety studies and that allows for the statistical comparison of concordance rates for glass and digital slide evaluation while minimizing time and effort for the involved personnel.

View Article and Find Full Text PDF
Article Synopsis
  • A group of 24 expert scientists from different places met in 2021 to discuss how to use the right words in studying how substances can affect health.
  • They focused on figuring out what's important when looking at lab results from tests done before new medicines are approved.
  • The workshop covered many topics, like how to handle different results, compare data, and understand how these findings connect to other study results.
View Article and Find Full Text PDF
Article Synopsis
  • A lot of new ideas have been created in the last 10 years to help reduce the use of animals in testing new medicines, with a cool new idea called Virtual Control Groups (VCGs).
  • The paper talks about the challenges of using VCGs, especially in studying body tissues, and mentions that scientists and regulators need to work together to make this happen smoothly.
  • They suggest that to prove VCGs really work, tests should be done with both VCGs and standard control groups at the same time, and later they could even replace the use of real animals in some cases!
View Article and Find Full Text PDF

Many pharmaceutical companies have recently elected to stop maintaining good laboratory practices (GLP) status of their R&D sites. Similar discussions have also been engaged in the (agro)chemical industry. This opinion paper examines the pros and cons of maintaining facility GLP status for the purposes of performing the pathology interpretation or peer reviews of GLP studies internally.

View Article and Find Full Text PDF

The European Society of Toxicologic Pathology organized an expert workshop in May 2018 to address adversity considerations related to thyroid follicular cell hypertrophy and/or hyperplasia (FCHH), which is a common finding in nonclinical toxicity studies that can have important implications for risk assessment of pharmaceuticals, food additives, and environmental chemicals. The broad goal of the workshop was to facilitate better alignment in toxicologic pathology and regulatory sciences on how to determine adversity of FCHH. Key objectives were to describe common mechanisms leading to thyroid FCHH and potential functional consequences; provide working criteria to assess adversity of FCHH in context of associated findings; and describe additional methods and experimental data that may influence adversity determinations.

View Article and Find Full Text PDF